Genomma Lab InternacionalB de CVMEX:LABB +0.46%66 Forward Rate of Return (Yacktman) % is 19.68% as of Mar. 2026, which is 17% above its 10-year median of 16.89. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.68 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 635 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks better than 88.35% on this metric.
Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Genomma Lab InternacionalB de CV's forward rate of return for was 19.68%.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's Forward Rate of Return (Yacktman) % or its related term are showing as below:
MEX:LABB'
s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 12.66 Med: 16.89 Max: 22.98
Current: 21.64
During the past 13 years, Genomma Lab InternacionalB de CV's highest Forward Rate of Return was 22.98. The lowest was 12.66. And the median was 16.89.
MEX:LABB's Forward Rate of Return (Yacktman) % is ranked better than 88.35% of 635
companies
in the Drug Manufacturers industry
Industry Median: 6.45
vs MEX:LABB: 21.64
Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Genomma Lab InternacionalB de CV (MEX:LABB) Forward Rate of Return (Yacktman) % Explanation
Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.
Be Aware
In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.
Genomma Lab InternacionalB de CV Forward Rate of Return (Yacktman) % Related Terms
Genomma Lab InternacionalB de CV Forward Rate of Return (Yacktman) % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV Forward Rate of Return (Yacktman) % Chart
MEX:LABB vs ZTS, UTHR, VTRS: Forward Rate of Return (Yacktman) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Forward Rate of Return (Yacktman) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Forward Rate of Return (Yacktman) % distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Forward Rate of Return (Yacktman) % falls into.
Genomma Lab InternacionalB de CV Forward Rate of Return (Yacktman) % Calculation
Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):
If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.
The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Rate of Return (Yacktman) % of 19.68% mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a Forward Rate of Return (Yacktman) % of 19.68% as of Mar. 2026. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 17% above median its historical median of 16.89. Over the past decade, Genomma Lab InternacionalB de CV's Forward Rate of Return (Yacktman) % has ranged from 12.66 to 22.98. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #74 out of 635 companies in the Drug Manufacturers industry, placing it in the top 11.7%.
Is Genomma Lab InternacionalB de CV's Forward Rate of Return (Yacktman) % too high?
Genomma Lab InternacionalB de CV's current Forward Rate of Return (Yacktman) % of 19.68% is 17% above median its 10-year median of 16.89. Over the past 10 years, this metric has ranged from a low of 12.66 to a high of 22.98. The Drug Manufacturers industry median Forward Rate of Return (Yacktman) % is 6.45. Genomma Lab InternacionalB de CV's value of 19.68% is 205.1% above this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #74 out of 635 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Forward Rate of Return (Yacktman) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #74 out of 635 companies for Forward Rate of Return (Yacktman) %. This places Genomma Lab InternacionalB de CV in the top 12% of its industry — outperforming the majority of peers. The industry median Forward Rate of Return (Yacktman) % is 6.45. Genomma Lab InternacionalB de CV's value of 19.68% is 205.1% above this benchmark. Historically, Genomma Lab InternacionalB de CV's own Forward Rate of Return (Yacktman) % has ranged from 12.66 to 22.98 over the past decade. While the company's 10-year median is 16.89 vs. the industry median of 6.45, Genomma Lab InternacionalB de CV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Rate of Return (Yacktman) % for a Drug Manufacturers company?
The median Forward Rate of Return (Yacktman) % among Drug Manufacturers companies is 6.45, based on 635 companies in the industry. Companies in the top quartile (top 25%) have a Forward Rate of Return (Yacktman) % significantly above this median, while those in the bottom quartile fall well below. However, Forward Rate of Return (Yacktman) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current Forward Rate of Return (Yacktman) % of 19.68% is 205.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Rate of Return (Yacktman) % mean?
A high Forward Rate of Return (Yacktman) % can signal that a stock is expensive relative to its fundamentals. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Forward Rate of Return (Yacktman) % is 6.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Forward Rate of Return (Yacktman) % is 19.68%, which is 17% above median its own 10-year median of 16.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.68, compared to a current price of MXN15.20 — trading 14% below its estimated fair value. The current Forward Rate of Return (Yacktman) % is 19.68%, which is 17% above median its 10-year median of 16.89 and 205.1% above the Drug Manufacturers industry median of 6.45. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Rate of Return (Yacktman) % calculated?
Forward Rate of Return (Yacktman) % is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Forward Rate of Return (Yacktman) % is 19.68% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.20 is trading 14% below its estimated GF Value™ of MXN17.68.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Forward Rate of Return (Yacktman) %: 19.68% (17% above median its 10-year median of 16.89)
GF Value™: MXN17.68 vs. price of MXN15.20 (14% below fair value)
Industry Position: 205.1% above the Drug Manufacturers median (#74 of 635)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Forward Rate of Return (Yacktman) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
